Optimal Antithrombotic Therapy Beyond 1-Year After Coronary Revascularization in Patients With Atrial Fibrillation.

Jihoon Kim Tae-Seok Seo Hyunsoo Kim Hyejeong Park Taek Kyu Park Joo-Myung Lee Jeong Hoon Yang Young Bin Song Jin Ho Choi Seung-Hyuk Choi Hyeon Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn

Published in: Journal of Korean medical science (2024)

As an antithrombotic therapy for AF beyond one year after coronary revascularization, NOAC monotherapy was associated with a similar risk of MACCE and a lower risk of major bleeding compared to NOAC plus antiplatelet combination therapy.

Keyphrases

combination therapy
atrial fibrillation
oral anticoagulants
percutaneous coronary intervention
coronary artery disease
coronary artery bypass grafting
coronary artery
heart failure
randomized controlled trial
acute coronary syndrome
stem cells
bone marrow
replacement therapy